Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Commentary

Our evolving understanding of primary aldosteronism

Ali Mehdi, MD, MEd, FACP, Pratibha Rao, MD, MPH and George Thomas, MD
Cleveland Clinic Journal of Medicine April 2021, 88 (4) 221-227; DOI: https://doi.org/10.3949/ccjm.88a.20166
Ali Mehdi
Department of Nephrology and Hypertension, Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
Pratibha Rao
Quality Improvement Officer, Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
George Thomas
Department of Nephrology and Hypertension, Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Our suggested algorithm for screening for and diagnosis of primary aldosteronism.

Tables

  • Figures
    • View popup
    TABLE 1

    Positive thresholds of biochemical testing for primary aldosteronism

    Screening testsMore conservativeMost widely acceptedMore liberal
    Aldosterone-renin ratio (ng/dL per ng/mL/hour)≥ 40≥ 30≥ 20
    Plasma aldosterone concentration (ng/dL)≥ 20≥ 15≥ 10
    Confirmation aldosterone suppression testsMore conservativeMore liberal
    With oral salt
    24-Hour urinary aldosterone excretion rate (μg)> 12–14> 10
    With intravenous saline
    Plasma aldosterone concentration (ng/dL)> 10> 5
    With fludrocortisone
    Seated plasma aldosterone concentration (ng/dL)> 6
    with plasma renin activity
    < 1 ng/mL/hour
    With captopril
    Plasma aldosterone concentration,< 30%
    decrease from baseline
    Aldosterone-renin ratio (ng/dL per ng/mL/hour)> 30> 20
    • Based on information in references 2 and 11.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 88 (4)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 4
1 Apr 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Our evolving understanding of primary aldosteronism
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Our evolving understanding of primary aldosteronism
Ali Mehdi, Pratibha Rao, George Thomas
Cleveland Clinic Journal of Medicine Apr 2021, 88 (4) 221-227; DOI: 10.3949/ccjm.88a.20166

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Our evolving understanding of primary aldosteronism
Ali Mehdi, Pratibha Rao, George Thomas
Cleveland Clinic Journal of Medicine Apr 2021, 88 (4) 221-227; DOI: 10.3949/ccjm.88a.20166
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • SERUM POTASSIUM IS NOT ALWAYS LOW
    • MORE COMMON THAN THOUGHT, BUT TRUE PREVALENCE IS UNCLEAR
    • CURRENT GUIDELINES FOR SCREENING AND DIAGNOSIS
    • LIMITATIONS OF CURRENT STATE
    • THE LOW-RENIN PHENOTYPE
    • HYPERALDOSTERONISM AS A SPECTRUM
    • WHERE DO WE GO FROM HERE?
    • EVOLVING UNDERSTANDING
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • 'I cant understand why others dont screen more: a qualitative study exploring why Australian general practitioners screen for primary aldosteronism
  • Google Scholar

More in this TOC Section

  • Respiratory virus season: Strategies for successful navigation
  • Matter of the heart: Prioritizing harm reduction in managing infective endocarditis associated with injection drug use
  • Effective but inaccessible antiobesity medications: A call for sharing responsibility for improving access to evidence-based care
Show more Commentary

Similar Articles

Subjects

  • Drug Therapy
  • Nephrology
  • Preventive Care

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire